53616-28-7

Upstream product

• 479-92-5 propyphenazone 

Downstream Products

• 91485-52-8 4-Isopropyl-2-methyl-3-(3-methyl-2-phenyl-morpholinomethyl)-1-phenyl-3-pyrazolin-5-on 
• 88913-10-4 3-(N-Hydroxy-N-methylaminomethyl)-4-isopropyl-2-methyl-1-phenyl-3-pyrazolin-5-on 
• 61672-58-0 5-Chloromethyl-4-isopropyl-1-methyl-2-phenyl-1,2-dihydro-pyrazol-3-one 
• 83957-89-5 5-(hydroxymethyl)-4-isopropyl-1-methyl-2-phenyl-1H-pyrazol-3(2H)-one 
• 83957-94-2 4-Isopropyl-2-methyl-3-(N-methyl-aminomethyl)-1-phenyl-3-pyrazolin-5-on 
• 525602-00-0 glycinyl-3-hydroxymethylpropyphenazone 
• 525602-01-1 3-[(hydroxyacetamido)methyl]-4-isopropyl-2-methyl-1-phenyl-3-pyrazolin-5-one 
• 83957-93-1 3-Formyl-4-isopropyl-2-methyl-1-phenyl-3-pyrazolin-5-on 
• 74512-64-4 1-phenyl-2-methyl-3-aminomethyl-4-isopropylpyrazolone 
• 74512-63-3 2-Hydroxy-N-(4-isopropyl-2-methyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-3-ylmethyl)-benzamide 
• 74512-62-2 Acetic acid 2-[(4-isopropyl-2-methyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-3-ylmethyl)-carbamoyl]-phenyl ester 

Relevant academic research and scientific papers

Biological and metabolic study of naproxen-propyphenazone mutual prodrug

Naproxen-propyphenazone (NAP-PP) esters were synthesized as prodrugs with the aim of improving the therapeutic index through prevention of gastrointestinal irritation and bleeding. The structures of the synthesized NAP-PP hybrid esters were confirmed by I

Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors

Improving the gastrointestinal safety profile of nonsteroidal anti-inflammatory drugs (NSAIDs) is an important goal. Herein, we report two strategies, using the nonacidic propyphenazone structure, with potential to overcome the side effects of NSAIDs. Pro

Synthesis, characterization, in vitro hydrolysis and pharmacodynamic profiles of potential novel mutual prodrugs of N-(2,3-xylyl anthranilic acid)

In present research work, we report the synthesis, in vitro hydrolysis study and pharmacological evaluation of new mutual prodrugs of mefenamic acid (MA) and 1,2 dihydro-1,5-dimethyl-4-(1-methylethyl)-2-phenylpyrazol-3-one with the aim of improving the th

New pyrazolones as 11b-HSD1 inhibitors for diabetes

Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.